More robust evidence for the efficacy of lithium in the long-term treatment of bipolar disorder: should lithium (again) be recommended as the single preferred first-line treatment?

With two recent systematic reviews and meta-analyses on the efficacy of lithium compared to placebo and other treatment options, it can now be concluded that lithium is the only drug that has been shown efficacious in the prevention of any mood episodes, manic episodes and depressive episodes in ran...

Descripción completa

Detalles Bibliográficos
Autor principal: Nolen, Willem A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312318/
https://www.ncbi.nlm.nih.gov/pubmed/25642404
http://dx.doi.org/10.1186/s40345-014-0017-6
_version_ 1782355106217328640
author Nolen, Willem A
author_facet Nolen, Willem A
author_sort Nolen, Willem A
collection PubMed
description With two recent systematic reviews and meta-analyses on the efficacy of lithium compared to placebo and other treatment options, it can now be concluded that lithium is the only drug that has been shown efficacious in the prevention of any mood episodes, manic episodes and depressive episodes in randomised trials not enriched for prior response to and tolerance of lithium. It is argued that lithium should be recommended as the single preferred first-line drug in the long-term treatment of bipolar disorder.
format Online
Article
Text
id pubmed-4312318
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-43123182015-02-01 More robust evidence for the efficacy of lithium in the long-term treatment of bipolar disorder: should lithium (again) be recommended as the single preferred first-line treatment? Nolen, Willem A Int J Bipolar Disord Letter to the Editor With two recent systematic reviews and meta-analyses on the efficacy of lithium compared to placebo and other treatment options, it can now be concluded that lithium is the only drug that has been shown efficacious in the prevention of any mood episodes, manic episodes and depressive episodes in randomised trials not enriched for prior response to and tolerance of lithium. It is argued that lithium should be recommended as the single preferred first-line drug in the long-term treatment of bipolar disorder. Springer Berlin Heidelberg 2015-01-31 /pmc/articles/PMC4312318/ /pubmed/25642404 http://dx.doi.org/10.1186/s40345-014-0017-6 Text en © Nolen; licensee Springer. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Letter to the Editor
Nolen, Willem A
More robust evidence for the efficacy of lithium in the long-term treatment of bipolar disorder: should lithium (again) be recommended as the single preferred first-line treatment?
title More robust evidence for the efficacy of lithium in the long-term treatment of bipolar disorder: should lithium (again) be recommended as the single preferred first-line treatment?
title_full More robust evidence for the efficacy of lithium in the long-term treatment of bipolar disorder: should lithium (again) be recommended as the single preferred first-line treatment?
title_fullStr More robust evidence for the efficacy of lithium in the long-term treatment of bipolar disorder: should lithium (again) be recommended as the single preferred first-line treatment?
title_full_unstemmed More robust evidence for the efficacy of lithium in the long-term treatment of bipolar disorder: should lithium (again) be recommended as the single preferred first-line treatment?
title_short More robust evidence for the efficacy of lithium in the long-term treatment of bipolar disorder: should lithium (again) be recommended as the single preferred first-line treatment?
title_sort more robust evidence for the efficacy of lithium in the long-term treatment of bipolar disorder: should lithium (again) be recommended as the single preferred first-line treatment?
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312318/
https://www.ncbi.nlm.nih.gov/pubmed/25642404
http://dx.doi.org/10.1186/s40345-014-0017-6
work_keys_str_mv AT nolenwillema morerobustevidencefortheefficacyoflithiuminthelongtermtreatmentofbipolardisordershouldlithiumagainberecommendedasthesinglepreferredfirstlinetreatment

Ejemplares similares